(Q44590937)

4 December 2017

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis (English)

1 reference

https://api.crossref.org/works/10.1056/NEJMOA035725

4 December 2017

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis (English)

1 reference

12 March 2024

0 references

Annmarie Hayes

2

1 reference

4 December 2017

Hang Lee

5

1 reference

4 December 2017

Joel S. Finkelstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14500805

12 March 2024

Joy L. Hunzelman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14500805

12 March 2024

Jason J. Wyland

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14500805

12 March 2024

Robert M. Neer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14500805

12 March 2024

language of work or name

English

0 references

publication date

20 September 2003

1 reference

full work available at URL

4 December 2017

https://doi.org/10.1056/nejmoa035725

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14500805

http://www.nejm.org/doi/pdf/10.1056/NEJMoa035725

12 March 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA035725

The New England Journal of Medicine

12 March 2024

published in

1 reference

4 December 2017

349

1 reference

4 December 2017

13

1 reference

4 December 2017

1216-1226

1 reference

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

4 December 2017

https://api.crossref.org/works/10.1056/NEJMOA035725

3

1 reference

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

4

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

5

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

6

1 reference

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

7

1 reference

Alendronate for the Treatment of Osteoporosis in Men

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

8

1 reference

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

9

1 reference

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

10

1 reference

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

11

1 reference

Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

12

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

13

1 reference

Total body bone mineral density in young children: influence of head bone mineral density.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

14

1 reference

Quantitative computed tomography for spinal density measurement. Factors affecting precision.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

15

1 reference

Biochemical markers in the assessment of bone disease

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

16

1 reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

18

1 reference

Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

19

1 reference

Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

20

1 reference

Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

21

1 reference

New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

23

1 reference

The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

24

1 reference

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

25

1 reference

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

27

1 reference

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

31

1 reference

Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

33

1 reference

Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

34

1 reference

Activation of the bone-derived latent TGF beta complex by isolated osteoclasts

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

35

1 reference

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

36

1 reference

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.

12 March 2024

https://api.crossref.org/works/10.1056/NEJMOA035725

37

1 reference

12 March 2024

Identifiers

DOI

10.1056/NEJMOA035725

1 reference

release_bowvyc7wcrdqvcpcxjlsd7usk4

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bowvyc7wcrdqvcpcxjlsd7usk4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference